In Q3 FY2026 (ended February 28, 2026), AngioDynamics reported revenue of $78.4 million, up 8.9% year-over-year. Net loss widened to $8.1 million from $4.4 million, and operating loss increased to $12.95 million. Diluted EPS was -$0.19, compared to -$0.11 a year ago.
•Revenue grew 8.9% YoY to $78.4 million.
•Net loss increased 83.4% to $8.1 million.
•Operating loss rose 29.8% to $12.95 million.
•Diluted EPS worsened to -$0.19 from -$0.11.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
AngioDynamics, Inc., a medical technology company designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and globally.
It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support.
Its portfolio also includes thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts, and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours
With other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage, as well as NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue
Peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. Additionally, it provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage.
Its portfolio also includes micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures, VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease, and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. Founded in 1988, AngioDynamics is headquartered in Latham, New York.
AngioDynamics, Inc. is a medical technology company that designs, manufactures, and sells medical, surgical, and diagnostic devices. Its products are used in treating peripheral vascular disease, as well as in oncology and surgical settings. Key offerings include the Auryon Atherectomy system, which uses an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium; the AlphaVac mechanical thrombectomy system for emergent mechanical aspiration; thrombolytic catheters that deliver drugs to dissolve blood clots; the AngioVac venous drainage cannula and extracorporeal circuit for circulatory support; and the NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for soft tissue. The company also provides peripheral products like angiographic catheters, guidewires, micro-introducer kits, and drainage catheters for various procedures.
Where is AngioDynamics (ANGO) listed and what currency does it trade in?
AngioDynamics, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ANGO. Its shares are traded in US Dollars (USD). The company is headquartered in the United States and operates primarily in the US and global markets.
What sector and industry does AngioDynamics (ANGO) belong to?
AngioDynamics operates in the Healthcare sector, specifically within the Medical Instruments & Supplies industry. This means the company develops and manufactures medical devices and supplies used by healthcare professionals for diagnosis, treatment, and surgical procedures. Its products are focused on peripheral vascular disease, oncology, and surgical applications.
What are the main product segments of AngioDynamics (ANGO)?
AngioDynamics' product portfolio includes several key segments. The Auryon Atherectomy system treats peripheral lesions while preserving vessel walls. The thrombus management portfolio features the AlphaVac mechanical thrombectomy system and thrombolytic catheters for dissolving blood clots, as well as the AngioVac system for venous drainage and extracorporeal circulatory support. The NanoKnife IRE Ablation System provides a non-thermal alternative for soft tissue ablation. Additionally, the company offers peripheral products such as angiographic catheters, guidewires, micro-introducer kits, and drainage catheters for abscess, nephrostomy, and biliary drainage. These products are used in hospitals and surgical centers globally.
Where does AngioDynamics (ANGO) operate geographically?
AngioDynamics is based in the United States and serves customers both domestically and internationally. The company's products are used in medical facilities across the US and globally. Its devices for peripheral vascular disease, oncology, and surgical settings are distributed to hospitals, clinics, and surgical centers worldwide. The company's global reach allows it to address a broad range of medical needs in various healthcare systems.